Tumour Registry Colorectal Cancer

Colorectal Cancer Clinical Trial

— TKK  

Official title:

Prospective and Retrospective Observation of the Adjuvant and Palliative Treatment Strategies in the Therapy of Colorectal Cancer in Germany

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00910819
• Other study ID #: IOM TKK
• Status: Completed
• Start date: September 2006
• Est. completion date: March 2022

Study information

• Verified date: May 2022
• Source: iOMEDICO AG
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

To describe treatment reality of patients with colorectal cancer treated by office-based and clinic-based medical oncologists in Germany.

Description:

The TKK is a prospective, longitudinal, nation wide cohort study with the purpose to record information on the antineoplastic treatment of colorectal cancer in Germany. The registry will follow patients for up to five years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics, biomarker testing and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented.

The impact of nutrition (CoNut) and physical activity (CoNut) on the course of the adjuvant disease will be examined, as well as long-term effects of adjuvant treatment (CoTox) and the final phase of the palliative process (CoLife). Based on the available data a prognostic score will be developed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 7000
• Est. completion date: March 2022
• Est. primary completion date: March 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Colorectal cancer

• 18 years and older

• Antineoplastic treatment

Exclusion Criteria:

• No colorectal cancer

• Below 18 years

• No antineoplastic treatment

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms

Locations

Country	Name	City	State
Germany	iOMEDICO AG	Freiburg	BW

Sponsors (3)

Lead Sponsor	Collaborator
iOMEDICO AG	Arbeitsgemeinschaft fur Internistische Onkologie, Arbeitskreis Klinische Studien

Country where clinical trial is conducted

Germany, 

References & Publications (2)

Marschner N, Arnold D, Engel E, Hutzschenreuter U, Rauh J, Freier W, Hartmann H, Frank M, Jänicke M. Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy — View Citation

Marschner N, Frank M, Vach W, Ladda E, Karcher A, Winter S, Jänicke M, Trarbach T. Development and validation of a novel prognostic score to predict survival in patients with metastatic colorectal cancer: the metastatic colorectal cancer score (mCCS). Colorectal Dis. 2019 Jul;21(7):816-826. doi: 10.1111/codi.14600. Epub 2019 Mar 18. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Course of Antineoplastic Treatment		5 years